Relief Therapeutics Holding Stock Gross Profit

RLFTF Stock  USD 4.33  0.13  2.91%   
Relief Therapeutics Holding fundamentals help investors to digest information that contributes to Relief Therapeutics' financial success or failures. It also enables traders to predict the movement of Relief OTC Stock. The fundamental analysis module provides a way to measure Relief Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Relief Therapeutics otc stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Relief Therapeutics Holding OTC Stock Gross Profit Analysis

Relief Therapeutics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

 = 

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current Relief Therapeutics Gross Profit

    
  2.57 M  
Most of Relief Therapeutics' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Relief Therapeutics Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Competition

According to the company disclosure, Relief Therapeutics Holding reported 2.57 M of gross profit. This is 99.89% lower than that of the Healthcare sector and 99.73% lower than that of the Biotechnology industry. The gross profit for all United States stocks is 99.99% higher than that of the company.

Relief Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Relief Therapeutics' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Relief Therapeutics could also be used in its relative valuation, which is a method of valuing Relief Therapeutics by comparing valuation metrics of similar companies.
Relief Therapeutics is currently under evaluation in gross profit category among its peers.

Relief Fundamentals

About Relief Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Relief Therapeutics Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relief Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relief Therapeutics Holding based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Relief OTC Stock

Relief Therapeutics financial ratios help investors to determine whether Relief OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Relief with respect to the benefits of owning Relief Therapeutics security.